Molecular Formula | C19H24N2O4 |
Molar Mass | 344.4 |
Density | 1.233±0.06 g/cm3(Predicted) |
Boling Point | 603.2±55.0 °C(Predicted) |
Flash Point | 318.6°C |
Solubility | DMSO: 20mg/mL, soluble |
Vapor Presure | 2.12E-15mmHg at 25°C |
Appearance | solid |
Color | off-white |
pKa | 8.95±0.50(Predicted) |
Stability | Stable. Incompatible with strong oxidizing agents. |
Refractive Index | 1.616 |
WGK Germany | 3 |
M-Nitro methyl paraben and benzyl chloride reaction, the resulting compound dissolved in chloroform, Dropwise into bromine reaction, reaction recrystallization treatment, the obtained compound and n-benzyl-1-p-methoxyphenyl-2-propylamine were refluxed in methyl ethyl ketone, the precipitate was removed by filtration, the filtrate was concentrated under reduced pressure, and the obtained substance was recrystallized from ethanol, the obtained compound was further reacted with sodium borohydride in ethanol, the solvent was distilled off under reduced pressure, and the remaining solution was extracted with benzene. After washing with water and drying, the obtained product is mixed with hydrochloric acid and methanol, iron powder is added to the reaction under stirring, the black precipitate is removed by filtration, the filtrate is further treated, and the obtained compound is in chloroform, formic acid-acetic anhydride mixture was added and the reaction was stirred. The obtained material was reacted together with Isopropanol (or ethanol) and palladium-carbon catalyst, filtered and concentrated to obtain crude formoterol. The crude product was converted to crystalline fumarate by treatment.
Japan within the mountains Development, March 1986 for the first time on the market. Long-acting, selective beta 2-receptor agonists, strong bronchodilating effect, as well as anti-allergic and edema-inhibiting effect. For the relief of bronchial asthma, acute and chronic bronchitis, asthmatic bronchitis and emphysema caused by Dyspnea and other symptoms.
LD50 male and female mice, male and female rats (mg/kg): 6700, 8310, 3130, 5580 orally; 72,71,98,100 intravenously, 240,210, 170,210 intraperitoneal injection; 640, 670, 1100, subcutaneous injection.